Abstract:The aim of the study was to validate Nuclear receptor-binding SET Domain NSD1 as a cancer drug target followed by the design of lead molecules against NSD1. TCGA clinical data, molecular expression techniques were used to validate the target and structure-based virtual screening was performed to design hits against NSD1. Clinical data analysis suggests the role of NSD1 in metastasis, prognosis and influence on overall survival in various malignancies. Furthermore, the mRNA and protein expression profile of NSD1 was evaluated in various cell lines. NSD1 was exploited as a target protein for in silico design of inhibitors using two major databases including ZINC15 and ChemDiv by structure-based virtual screening approach. Virtual screening was performed using the pharmacophore hypothesis designed with a protein complex S-adenosyl-l-methionine (SAM) as an endogenous ligand. Subsequently, a combined score was used to distinguish the top 10 compounds from the docking screened compounds having high performance in all four scores (docking score, XP, Gscore, PhaseScreenScore, and MMGBSA delta G Bind). Finally, the top three Zinc compounds were subjected to molecular dynamic simulation. The binding MMGBSA data suggests that ZINC000257261703 and ZINC000012405780 can be taken for in vitro and in vivo studies as they have lesser MMGBSA energy towards the cofactor binding site of NSD1 than the sinefungin. Our data validates NSD1 as a cancer drug target and provides promising structures that can be utilized for further lead optimization and rational drug design to open new gateways in the field of cancer therapeutics.

Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors

Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2

Identification of Novel Potent NSD2-PWWP1 Ligands Using Structure-Based Design and Computational Approaches

Identification of potential methyltransferase NSD2 enzymatic inhibitors through a multi-step structure-based drug design

Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs

Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2

Structural Modification and Pharmacological Evaluation of Substituted Quinoline-5,8-diones As Potent NSD2 Inhibitors

Covalent inhibition of NSD1 histone methyltransferase

Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader

Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors

Recent Advances in Nuclear Receptor-Binding SET Domain 2 (NSD2) Inhibitors: an Update and Perspectives

NSD Family Proteins: Rising Stars As Therapeutic Targets

Target validation and structure-based virtual screening to Discover potential lead molecules against the oncogenic NSD1 histone methyltransferase

Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.

Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2

Prospect of targeting lysine methyltransferase NSD3 for tumor therapy

Identification of Novel Hits of the NSD1 SET Domain by NMR Fragment-Based Screening

NSD3: Advances in cancer therapeutic potential and inhibitors research

Discovering New Metallo-Deubiquitinase CSN5 Inhibitors by a Non-Catalytic Activity Assay Platform

Synthesis and Structure-Activity Relationship Studies of LLY-507 Analogues As SMYD2 Inhibitors.

Identification of novel and potent dual-targeting HDAC1/SPOP inhibitors using structure-based virtual screening, molecular dynamics simulation and evaluation of in vitro and in vivo antitumor activity